Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

8.7%

2 terminated/withdrawn out of 23 trials

Success Rate

88.2%

+1.7% vs industry average

Late-Stage Pipeline

35%

8 trials in Phase 3/4

Results Transparency

7%

1 of 15 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
9(39.1%)
Phase 2
6(26.1%)
Phase 3
6(26.1%)
Phase 4
2(8.7%)
23Total
Phase 1(9)
Phase 2(6)
Phase 3(6)
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials
NCT06757283Phase 3Not Yet Recruiting

ZyVac-TCV Bangladesh Study

Role: collaborator

NCT06815835Phase 3Not Yet Recruiting

Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months

Role: collaborator

NCT05515367Phase 4Recruiting

A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study)

Role: lead

NCT06398808Phase 2Completed

A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral Aminosalicylates

Role: lead

NCT05981040Phase 2Completed

Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis

Role: lead

NCT05911828Phase 1Recruiting

A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers

Role: lead

NCT05283837Phase 3Completed

A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)

Role: lead

NCT05872269Phase 4Recruiting

A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities

Role: lead

NCT04480138Phase 2Terminated

Pegylated Interferon - α2b With SARSCoV- 2 (COVID-19)

Role: lead

NCT05206201Phase 1Completed

A Study Of Zy-19489 Administered Via Oral Route To Investigate The Safety, Tolerability And Pharmacokinetics In Healthy Adult Human Subjects

Role: lead

NCT05186051Phase 2Completed

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS)

Role: lead

NCT04667533Phase 1Completed

Desidustat in the Treatment of Chemotherapy Induced Anemia

Role: lead

NCT04215120Phase 3Completed

Desidustat in the Treatment of Anemia in CKD on Dialysis Patients

Role: lead

NCT04012957Phase 3Completed

Desidustat in the Treatment of Anemia in CKD

Role: lead

NCT04972188Phase 1Completed

A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ZYIL1 Following Oral Administration in Healthy Volunteers

Role: lead

NCT04731324Phase 1Completed

Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ZYIL1 Following Oral Administration in Healthy Volunteers

Role: lead

NCT04463602Phase 2Completed

Desidustat in the Management of COVID-19 Patients

Role: lead

NCT02005666Phase 3Completed

To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel

Role: lead

NCT02620592Phase 1Completed

Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PKs) of ZYDPLA1 Following Oral Administration in Healthy Volunteers

Role: lead

NCT01543269Phase 1Terminated

A Clinical Study to Evaluate the Safety,Tolerability and PK of ZYT1, Following Oral Administration in Healthy Volunteers

Role: lead